SCHEMBL2659296

SCHEMBL2659296

O=C(O)CCNC(=O)c1ccc(C(CC(=O)c2ccc(Oc3ccccc3)cc2)C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.48
GCGR P47871 14/20 0.44
ADCY6 O43306 2/20 0.44
ADCY3 O60266 2/20 0.44
ADCY9 O60503 2/20 0.44
ADCY5 O95622 2/20 0.44
ADCY8 P40145 2/20 0.44
ADCY7 P51828 2/20 0.44
ADCY2 Q08462 2/20 0.44
ADCY1 Q08828 2/20 0.44
ADCY4 Q8NFM4 2/20 0.44
EGLN2 Q96KS0 1/20 0.44
TACR1 P25103 1/20 0.43
GCG P01275 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP2 P08253 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654643 0.90 GCGR (0.55) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2654410 0.87 GCGR (0.54) MAPK14GCGRADCY6ADCY3ADCY9
SCHEMBL2648741 0.87 GCGR (0.54) MAPK14GCGRADCY6ADCY3ADCY9
SCHEMBL2655272 0.87 ALDH1A1 (0.47) GCGRTACR1GCG
SCHEMBL2654576 0.87 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2660882 0.87 GCG (0.43) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2665152 0.86 GCGR (0.55) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2653505 0.86 GCGR (0.45) GCGRCA12CA1CA2MMP2
SCHEMBL2647001 0.86 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL6758435 0.86 GCGR (0.54) GCGRADCY6ADCY3ADCY9ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152750-A1 Novel glucagon antagonists NOVO NORDISK A/S (DK) 2004-08-05 US disclosed
WO-2004056763-A2 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed
WO-2004056763-A2 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152750-A1 Novel glucagon antagonists GLP1R, GCGR, GIPR MAPK14 1428/4885GCGR 2/4885ADCY6 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.